immunodiagnosticsystems
We use tools, such as cookies, to enable essential services and functionality on our site. We also use this to collect data on how our visitors interact with our site, products and services. By clicking accept, you agree to our use of these tools for advertising, analytics and support. I Accept Privacy Policy Cookie Policy
immunodiagnosticsystems
Home ยป Investor Relations
As a leading in-vitro diagnostic solution provider to the clinical laboratory market, we develop, manufacture and market innovative immunoassays and automated immunoanalyser technologies to provide improved diagnostic outcomes for patients.
Clinical and research laboratories across the world choose our high quality assays, automated solutions and expertise when diagnosing, monitoring or researching conditions to improve outcomes and enhance patient value.
IDS was acquired by PerkinElmer (UK) Holdings Limited on 12 July 2021, and delisted from the AIM market on 13 July 2021. As a result this Investor Relations section of the website is no longer maintained, but has been retained for archival purposes.
As a leading in-vitro diagnostic solution provider to the clinical laboratory market, we develop, manufacture and market innovative immunoassays and automated immunoanalyser technologies to provide improved diagnostic outcomes for patients.
Clinical and research laboratories across the world choose our high quality assays, automated solutions and expertise when diagnosing, monitoring or researching conditions to improve outcomes and enhance patient value.
IDS was acquired by PerkinElmer (UK) Holdings Limited on 12 July 2021, and delisted from the AIM market on 13 July 2021. As a result this Investor Relations section of the website is no longer maintained, but has been retained for archival purposes.
